GNPDA2

Across TCGA pan-cancer cohorts, GNPDA2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GNPDA2 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher GNPDA2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GNPDA2 expression acts as an unfavorable survival marker.

SKCM, COAD, and LUSC are the cancer types where GNPDA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.188	0.784	<.001	36	view →
COAD	OS	Median	All	0.001	0.871	<.001	18	view →
LUSC	OS	Median	II,III,IV	0.133	0.732	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GNPDA2–SKCM (OS)

Open the SKCM breakdown →